Abstracts tagged "interstitial lung disease"

Abstract Number: 0266 • ACR Convergence 2023
E-selectin, ICAM-1 and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases
Verónica Pulito-Cueto¹, Sara Remuzgo-Martinez², Fernanda Genre Romero², Belén Atienza-Mateo³, Victor Mora-Cuesta⁴, David Iturbe-Fernández⁴, Leticia Lera-Gómez⁵, María Sebastián-Mora¹, Virginia Portilla¹, Alfonso Corrales¹, Ricardo Blanco¹, Jose Cifrian⁶, Miguel A Gonzalez-Gay⁷ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, ⁷IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) constitutes one of the most critical comorbidities in autoimmune diseases (AD), particularly in rheumatoid arthritis (RA) and systemic sclerosis (SSc)…
Abstract Number: 0627 • ACR Convergence 2023
Clinical Significance of Anti-Ro/SSA Antibodies in Patients with Systemic Sclerosis: A Study from the EUSTAR Database
Blaz Burja¹, Marouane Boubaya², Patricia Carreira³, Christina Bergmann⁴, Lidia P Ananieva⁵, Gabriela Riemekasten⁶, Okada Masado⁷, Jeska de Vries-Bouwstra⁸, Edoardo Rosato⁹, Marie-Elise Truchetet¹⁰, Nicoletta Del Papa¹¹, Antonella Marcoccia¹², FABIOLA ATZENI¹³, Tim Schmeiser¹⁴, Madelon Vonk¹⁵, Francesco Del Galdo¹⁶, Oliver Distler¹⁷ and Muriel Elhai¹⁸, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Department of Clinical Research, CHU Avicenne, APHP, Bobigny, France, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Department Internal Medicine, University Hospital Erlangen, Germany, Erlangen, Germany, ⁵V.A. Nasonova Research Institute Of Rheumatology Russian Federation, Moscow, Russia, ⁶University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ⁷St.Luke's International Hospital Immuno-Rheumatology Center, Tokyo, Japan, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy, ¹⁰Bordeaux University Hospital, Bordeaux, France, ¹¹Scleroderma Clinic, UOC Reumatologia Clinica, ASST G. Pini-CTO, Milano, Italy, ¹²Centro Di Riferimento Interdisciplinare Per La Sclerosi Sistemica, Rome, Italy, ¹³Rheumatology Unit, Univerity of Messina, Messina, Italy, ¹⁴Krankenhaus St. Josef, Wuppertal-Elberfeld, Germany, ¹⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁶University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ¹⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland
Background/Purpose: Despite the progress in understanding the patient heterogeneity in systemic sclerosis (SSc) based on SSc-specific antibodies, better risk stratification is needed. SSc non-specific antibodies…
Abstract Number: 0774 • ACR Convergence 2023
Deciphering Rheumatoid Arthritis-associated Interstitial Lung Disease Phenotypes Using Unsupervised Hierarchical Clustering Analysis: Results from a Large Collaborative International Study
Pierre-Antoine Juge¹, Benjamin Granger², Lina El Houari³, Gregory McDermott⁴, Tracy J. Doyle⁴, Clive Kelly⁵, Gouri M Koduri⁶, Robert Vassallo⁷, Amarilys Alarcon Calderon⁷, Umut Kalyoncu⁸, Antonio Gonzalez⁹, Natalia Mena Vazquez¹⁰, Marta Rojas¹¹, Raquel Dos-Santos¹², Miriam Retuerto-Guerrero¹³, Cristina Vadillo-Font¹⁴, PALOMA VELA¹⁵, Antonio Fernandez-Nebro¹⁶, Alejandro Escudero-Contreras¹⁷, Eva Perez-Pampin¹⁸, Charlotte Hyldgaard¹⁹, Antoine Froidure²⁰, Patrick Durez²¹, Jorge Rojas Serrano²², Coline van Moorsel²³, Jan C Grutters²³, Leticia Kawano-Dourado²⁴, Charlotte Lucas²⁵, Stephane Jouneau²⁶, Raimon Sanmarti²⁷, Raul Castellanos Moreira²⁸, Katarina Antoniou²⁹, Maria Molina molina³⁰, joshua Solomon³¹, Sophia raia³¹, Miguel A Gonzalez-Gay³², Belén Atienza-Mateo³³, Sofia Flouda³⁴, Effrosyni Manali³⁴, Boumpas Dimitrios³⁵, Spyros Papiris³⁴, THEOFANIS KARAGEORGAS³⁶, Marco Sebastiani³⁷, Andreina Manfredi³⁸, Ana Catarina Duarte³⁹, Santos Castañeda⁴⁰, Lorenzo Cavagna⁴¹, Bruno Crestani⁴², Jeffrey Sparks⁴³ and Philippe Dieudé⁴⁴, ¹Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ²Sorbonne Université, INSERM, and Pitié Salpêtrière Hospital, Paris, France, ³Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France, ⁴Brigham and Women's Hospital, Boston, MA, ⁵James Cook University Hospital, Middlesbrough, United Kingdom, ⁶Southend University Hospitals NHS Trust, Essex, United Kingdom, ⁷Mayo Clinic, Rochester, MN, ⁸Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁹Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ¹⁰IBIMA, Málaga, Spain, ¹¹Hospital Universitario Reina Sofía, Cordoba, Spain, ¹²Clinical University Hospital in Santiago de Compostela, Santiago de Compostela, Spain, ¹³Rheumatology, Hospital Universitario de León, León, Spain, ¹⁴Hospital Clínico San Carlos – Instituto Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ¹⁵Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹⁶Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁷Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain, ¹⁸Rheumatology Department Complejo Hospitalario Universitario Santiago, Santiago de compostela, Spain, ¹⁹Silkeborg Regional Hospital, Silkeborg, Denmark, ²⁰Université Catholique de Louvain, Louvain, Belgium, ²¹UCLouvain, Brussels, Belgium, ²²Hospital Angeles Villahermosa, Ciudad de Mexico, Mexico, ²³St. Antonius Hospital, Nieuwegein, Netherlands, ²⁴Hospital do Coração (HCor), São Paulo, Brazil, ²⁵CHU, Rennes, France, ²⁶Amicus, Boca Raton, FL, ²⁷Hospital Clinic, Rheumatology, Barcelona, Spain, ²⁸Hospital Clínic de Barcelona, Madrid, Spain, ²⁹University of Crete, Heraklion, Greece, ³⁰IDIBELL Bellvitge Biomedical Research Institute, Barcelona, Spain, ³¹National Jewish Health, Denver, CO, ³²IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ³³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁴Unit of Attikon University Hospital, Athens, Greece, ³⁵National and Kapodistrian University of Athens, Athens, Greece, ³⁶n/a, Athina, Greece, ³⁷Azienda Policlinico di Modena, Modena, Italy, ³⁸University of Modena, Modena, Italy, ³⁹Hospital Garcia de Orta, Almada, Portugal, ⁴⁰Hospital Universitario de la Princesa, Madrid, Spain, ⁴¹Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁴²Hopital Bichat, Paris University, Paris, France, ⁴³Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁴⁴Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France
Background/Purpose: RA-associated interstitial lung disease (ILD) is not a single entity as illustrated by different HRCT patterns, different risk factors and prognoses suggesting heterogenous phenotypes.…
Abstract Number: 1167 • ACR Convergence 2023
Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai³ and Moe Tokunaga(Sakamoto)³, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan, ³Rheumatology, Center for Autoimmune diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan
Background/Purpose: MDA5-DM is characterized by high mortality due to rapid progressive ILD. We reported that in MDA-5DM, (1) RIG-1-like receptor signaling is enhanced, (2) antiviral…
Abstract Number: 1660 • ACR Convergence 2023
Still’s Disease Patients with High Interferon-stimulated Gene Expression Have Enrichment of Rare, de Novo and Recessive Protein Altering Variants in Innate Immune Pathways
Mariana Correia Marques¹, Zuoming Deng², Navid Chowdhury², Elizabeth Schmitz³, Alana Platukus⁴, Stephen Brooks⁵, Carol Lake², Ly-Lan Bergeron², Michelle Millwood² and Michael Ombrello⁶, ¹National Institute of Arthritis & Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), St. Louis, MO, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Philadelphia, PA, ⁵Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skins Diseases, National Institutes of Health, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Still’s disease (systemic juvenile idiopathic arthritis in children, adult-onset Still’s disease in adults) is an enigmatic inflammatory condition that affects people of all ages.…
Abstract Number: 1959 • ACR Convergence 2023
Quantitative Scoring of High Resolution Chest Computed Tomography (HRCT) Images in Myositis and Antisynthetase Syndrome Related Interstitial Lung Disease in Comparison to Scleroderma Related Interstitial Lung Disease
Sangmee Bae¹, Fereidoun Abtin², Grace Kim³, Siamak Moghadam-Kia⁴, Chester V. Oddis⁵, Lila Pourzand², Didem Saygin⁵, Daniel Sullivan⁶, Koichi Yamaguchi⁷, Donald Tashkin³, Christina Charles-Schoeman⁸, Jonathan Goldin³ and Rohit Aggarwal⁵, ¹UCLA Rheumatology, Los Angeles, CA, ²UCLA Radiological Sciences, Los Angeles, CA, ³University of California Los Angeles, Los Angeles, CA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶UCLA Pulmonology, Pittsburgh, PA, ⁷University of Pittsburgh Medical Center Rheumatology, Pittsburgh, PA, ⁸UCLA Medical Center, Santa Monica, CA
Background/Purpose: High resolution computed tomography (HRCT) of the chest has become an important modality in the evaluation of interstitial lung disease (ILD). A quantitative CT…
Abstract Number: 2572 • ACR Convergence 2023
Autoantibody Profile of Autoimmune Driven Interstitial Lung Disease as Compared to Idiopathic Pulmonary Fibrosis and Association of Autoantibodies with Survival
Elena Joerns¹, Chad Newton², Stanislav Kolenikov³, Jeffrey Sparks⁴ and David Karp⁵, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX, ³NORC at the University of Chicago, Columbia, MO, ⁴Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁵UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The term interstitial pneumonia with autoimmune features (IPAF) describes patients with interstitial lung disease (ILD) and features of autoimmunity, that do not fulfill classification…
Abstract Number: 0286 • ACR Convergence 2023
Relationship Between High Resolution Computed Tomography(HRCT) Quantitative Scores and Physiological and Clinical Features in Antisynthetase Syndrome Related Interstitial Lung Disease
Sangmee Bae¹, Fereidoun Abtin², Grace Kim³, Daniela Markovic⁴, Siamak Moghadam-Kia⁵, Chester V. Oddis⁶, Lila Pourzand², Didem Saygin⁶, Daniel Sullivan⁷, Koichi Yamaguchi⁵, Donald Tashkin³, Christina Charles-Schoeman⁸, Jonathan Goldin³ and Rohit Aggarwal⁶, ¹UCLA Rheumatology, Los Angeles, CA, ²UCLA Radiological Sciences, Los Angeles, CA, ³University of California Los Angeles, Los Angeles, CA, ⁴UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁵University of Pittsburgh Medical Center Rheumatology, Pittsburgh, PA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷UCLA Pulmonology, Pittsburgh, PA, ⁸UCLA Medical Center, Santa Monica, CA
Background/Purpose: High resolution chest computed tomography (HRCT) plays an important role in the clinical evaluation of interstitial lung disease (ILD) by demonstrating the extent of…
Abstract Number: 0628 • ACR Convergence 2023
Interstitial Lung Disease in Very Early Systemic Sclerosis
Sinziana Muraru¹, Carina Mihai¹, Anna-Maria Hoffmann-Vold², Cosimo Bruni¹, Muriel Elhai³, Mike Becker⁴, Suzana Jordan¹, Alexandru Garaiman¹, Oliver Distler¹ and Rucsandra Dobrota¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) affects around 50% of patients with systemic sclerosis (SSc) and is the main cause of mortality. Preliminary data from small…
Abstract Number: 0789 • ACR Convergence 2023
Telomere Length of Peripheral Blood Cells Predicts More Severe Pulmonary Disease and Worse Survival in Systemic Sclerosis
Monica Yang¹, Shuo Liu², Seoyeon Lee³, Sarah French¹, Paul Wolters¹ and Francesco Boin⁴, ¹University of California San Francisco, San Francisco, CA, ²Fourth Hospital of China Medical University, Shenyang, China, ³Yale University School of Medicine, New Haven, CT, ⁴Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Peripheral blood leukocyte telomere length (PBL-TL) has been associated with disease and organ specific morbidity and mortality in conditions associated with pulmonary fibrosis including…
Abstract Number: 1168 • ACR Convergence 2023
Evaluation of Agreement Between Functional and Radiological Changes in Idiopathic Inflammatory Myositis (IIM) Associated Interstitial Lung Disease (ILD)
Sonali Narain¹, Can Hu², Michael Liu¹, Himanshu Vashistha¹, Kourosh Shargani³ and Galina Marder¹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Fort Lee, NJ, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY
Background/Purpose: ILD is a major cause of morbidity and mortality in IIM. The diagnosis and progression of ILD often relies on high resolution computed tomography…
Abstract Number: 1668 • ACR Convergence 2023
Cell Specific Molecular Profiling of Scleroderma Associated Interstitial Lung Disease Subtypes
Monica Yang¹, Fred Deiter¹, Emily Flynn¹, Jessica Neely¹, Seoyeon Lee², John Greenland¹, Marina Sirota³ and Paul Wolters¹, ¹University of California San Francisco, San Francisco, CA, ²Yale University School of Medicine, New Haven, CT, ³Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA
Background/Purpose: Interstitial lung disease (ILD) is present in up to 90% of patients with systemic sclerosis (SSc) and the leading cause of SSc-related mortality. SSc-ILD…
Abstract Number: 2098 • ACR Convergence 2023
Contribution of Rare Deleterious Exonic Variants in Telomere Related Genes to Interstitial Lung Disease Risk in Patients with Rheumatoid Arthritis
Pierre-Antoine Juge¹, Leticia Kawano-Dourado², Steven Gazal³, Gregory McDermott⁴, Keigo Hayashi⁴, Jing Cui⁵, Marie-Pierre Debray⁶, Lidwine Stervinou-Wemeau⁷, Syvain Marchand-Adam⁸, Christophe Richez⁹, Hilario Nunes¹⁰, Jérôme Avouac¹¹, Rene-Marc Flipo¹², Vincent Cottin¹³, Martin Soubrier¹⁴, Nathalie Saidenberg Kermanac'h¹⁰, Caroline Kannengiesser¹⁵, Raphael Borie¹⁶, Bruno Crestani¹⁷, Tracy J. Doyle⁴, Soumya Raychaudhuri⁴, Elizabeth Karlson⁴, Jeffrey Sparks¹⁸ and Philippe Dieudé¹⁹, ¹Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ²Hospital do Coração (HCor), São Paulo, Brazil, ³University of South California, Los Angeles, CA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶CHU Bichat, Radiology, Paris, France, ⁷CHRU de Lille, Lille, France, ⁸CHU Tours, Tours, France, ⁹Université de Bordeaux, Bordeaux, France, ¹⁰CHU Avicenne, Bobigny, France, ¹¹Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France, ¹²La Lettre du Rhumatologue, Paris, France, ¹³Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹⁴Gabriel-Montpied Hospital, Clermont-ferrand, France, ¹⁵CHU Bichat, Paris, France, ¹⁶Bichat-Claude Bernard, Universite de Paris, Paris, France, ¹⁷Hopital Bichat, Paris University, Paris, France, ¹⁸Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁹Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France
Background/Purpose: RA-associated interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) share genetic risk factors such as MUC5B rs35705950. The exact role of telomere related…
Abstract Number: 2573 • ACR Convergence 2023
Prevalence of Pulmonary Hypertension in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features and Its Effect on Lung Disease Progression and Mortality
Michelle Ghebranious, Elena Joerns, Traci Adams and Trushil Shah, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a subset of interstitial lung disease (ILD) that manifests with interstitial pneumonia and features of autoimmunity while…
Abstract Number: 0287 • ACR Convergence 2023
6-Minute Walk Distance Associates with Physiologic Measures and Physician/Patient Reported Outcomes in Myositis Related Interstitial Lung Disease
Sangmee Bae¹, Fereidoun Abtin², Grace Kim³, Daniela Markovic⁴, Siamak Moghadam-Kia⁵, Chester V. Oddis⁶, Lila Pourzand², Didem Saygin⁶, Daniel Sullivan⁷, Koichi Yamaguchi⁸, Donald Tashkin³, Christina Charles-Schoeman⁹, Jonathan Goldin³ and Rohit Aggarwal⁶, ¹UCLA Rheumatology, Los Angeles, CA, ²UCLA Radiological Sciences, Los Angeles, CA, ³University of California Los Angeles, Los Angeles, CA, ⁴UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁵University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷UCLA Pulmonology, Pittsburgh, PA, ⁸University of Pittsburgh Medical Center Rheumatology, Pittsburgh, PA, ⁹UCLA Medical Center, Santa Monica, CA
Background/Purpose: The 6 minute walk distance (6MWD) provides a global evaluation of sub-maximal exercise capacity that is easily performed and highly reproducible, and is used…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].